PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för pimasertib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

31 hits

Bibliografisk träff 2023-04-25

Three generations of mTOR kinase inhibitors in the activation of the apoptosis process in melanoma cells.

Ciołczyk-Wierzbicka D, Krawczyk A, Zarzycka M, Zemanek G, Wierzbicki K.

J Cell Commun Signal · research-article; journal article · DOI 10.1007/s12079-023-00748-9

Bibliografisk träff 2021-09-01

Allosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation.

Gonzalez-Del Pino GL, Li K, Park E, Schmoker AM, Ha BH, Eck MJ.

Proc Natl Acad Sci U S A · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1073/pnas.2107207118

Bibliografisk träff 2021-01-01

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.

Delord JP, Italiano A, Awada A, Aftimos P, Houédé N, Lebbé C, Pages C, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Faivre S, Gomez-Roca C, Scheuler A, Massimini G, Raymond E.

Target Oncol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s11523-020-00768-0

Bibliografisk träff 2021-01-01

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.

Lebbé C, Italiano A, Houédé N, Awada A, Aftimos P, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Raymond E, Faivre S, Pages C, Gomez-Roca C, Schueler A, Goodstal S, Massimini G, Delord JP.

Target Oncol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s11523-020-00767-1

Bibliografisk träff 2020-06-29

Pimasertib Versus Dacarbazine in Patients With Unresectable <i>NRAS</i>-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover.

Lebbé C, Dutriaux C, Lesimple T, Kruit W, Kerger J, Thomas L, Guillot B, Braud F, Garbe C, Grob JJ, Loquai C, Ferraresi V, Robert C, Vasey P, Conry R, Isaacs R, Espinosa E, Schueler A, Massimini G, Dréno B.

Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers12071727

Bibliografisk träff 2019-12-20

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.

Arend RC, Davis AM, Chimiczewski P, O'Malley DM, Provencher D, Vergote I, Ghamande S, Birrer MJ.

Gynecol Oncol · clinical trial, phase ii; randomized controlled trial; journal article · DOI 10.1016/j.ygyno.2019.12.002

Bibliografisk träff 2019-10-04

mTOR inhibitor everolimus reduces invasiveness of melanoma cells.

Ciołczyk-Wierzbicka D, Gil D, Zarzycka M, Laidler P.

Hum Cell · research-article; journal article · DOI 10.1007/s13577-019-00270-4

Bibliografisk träff 2019-09-03

Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma.

Yamazaki K, Doi T, Ikeda M, Okusaka T, Schueler A, Watanabe M, Ohtsu A.

Cancer Chemother Pharmacol · multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s00280-019-03924-0

Bibliografisk träff 2019-03-08

mTOR inhibitor Everolimus-induced apoptosis in melanoma cells.

Ciołczyk-Wierzbicka D, Zarzycka M, Gil D, Laidler P.

J Cell Commun Signal · research-article; journal article · DOI 10.1007/s12079-019-00510-0

Bibliografisk träff 2018-12-26

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.

de Weger VA, de Jonge M, Langenberg MHG, Schellens JHM, Lolkema M, Varga A, Demers B, Thomas K, Hsu K, Tuffal G, Goodstal S, Macé S, Deutsch E.

Br J Cancer · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1038/s41416-018-0355-8

Bibliografisk träff 2018-11-14

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.

Schram AM, Gandhi L, Mita MM, Damstrup L, Campana F, Hidalgo M, Grande E, Hyman DM, Heist RS.

Br J Cancer · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1038/s41416-018-0322-4

Bibliografisk träff 2018-08-09

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.

Van Cutsem E, Hidalgo M, Canon JL, Macarulla T, Bazin I, Poddubskaya E, Manojlovic N, Radenkovic D, Verslype C, Raymond E, Cubillo A, Schueler A, Zhao C, Hammel P.

Int J Cancer · clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1002/ijc.31603

Bibliografisk träff 2018-08-01

Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.

Srinivas NR.

Eur J Drug Metab Pharmacokinet · review; journal article · DOI 10.1007/s13318-018-0466-x

Bibliografisk träff 2018-01-16

Pimasertib-associated ophthalmological adverse events.

van Dijk EHC, Kruit WHJ, Jager MJ, Luyten GPM, Vingerling JR, Boon CJF.

Acta Ophthalmol · journal article; observational study · DOI 10.1111/aos.13677

Bibliografisk träff 2017-03-13

Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients.

Mahadevan D, Mita M, Richards D, McClay E, Heist RS, Kumar A, Sundararajan S, Naing A.

Cancer Chemother Pharmacol · comparative study; research support, non-u.s. gov't; multicenter study; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s00280-017-3258-0

Bibliografisk träff 2017-02-13

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.

Mita M, Fu S, Piha-Paul SA, Janku F, Mita A, Natale R, Guo W, Zhao C, Kurzrock R, Naing A.

Invest New Drugs · research-article; clinical trial, phase i; journal article · DOI 10.1007/s10637-017-0442-3

Bibliografisk träff 2016-12-01

Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors.

Scheible H, Kraetzer F, Marx A, Johne A, Wimmer E.

Drug Metab Dispos · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1124/dmd.116.072934

Bibliografisk träff 2016-11-01

Correction: The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Response.

Författaruppgift saknas

Clin Cancer Res · published erratum; journal article · DOI 10.1158/1078-0432.ccr-16-1542

Bibliografisk träff 2016-09-19

Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.

von Richter O, Massimini G, Scheible H, Udvaros I, Johne A.

Br J Clin Pharmacol · clinical trial; research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/bcp.13078

Bibliografisk träff 2016-05-01

The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Letter.

Leon LG, Funel N, Peters GJ, Avan A, Vistoli F, Boggi U, Giovannetti E.

Clin Cancer Res · letter; comment; research support, non-u.s. gov't · DOI 10.1158/1078-0432.ccr-16-0259

Bibliografisk träff 2016-05-01

The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Response.

Vena F, Hartley JA, Hochhauser D.

Clin Cancer Res · letter; comment; research support, non-u.s. gov't · DOI 10.1158/1078-0432.ccr-16-0566

Bibliografisk träff 2016-03-08

Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.

Gaudio E, Tarantelli C, Kwee I, Barassi C, Bernasconi E, Rinaldi A, Ponzoni M, Cascione L, Targa A, Stathis A, Goodstal S, Zucca E, Bertoni F.

Ann Oncol · journal article · DOI 10.1093/annonc/mdw131

Bibliografisk träff 2016-02-26

Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib.

Sala V, Gallo S, Gatti S, Medico E, Vigna E, Cantarella D, Fontani L, Natale M, Cimino J, Morello M, Comoglio PM, Ponzetto A, Crepaldi T.

J Mol Cell Cardiol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.yjmcc.2016.02.017

Bibliografisk träff 2016-01-01

PIMASERTIB AND SEROUS RETINAL DETACHMENTS.

AlAli A, Bushehri A, Park JC, Krema H, Lam WC.

Retin Cases Brief Rep · journal article; case reports; case-report · DOI 10.1097/icb.0000000000000228

Bibliografisk träff 2015-12-11

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies.

Ravandi F, Pigneux A, DeAngelo DJ, Raffoux E, Delaunay J, Thomas X, Kadia T, Kantarjian H, Scheuenpflug J, Zhao C, Guo W, Smith BD.

Blood Cancer J · letter; clinical trial; research support, non-u.s. gov't · DOI 10.1038/bcj.2015.103

Bibliografisk träff 2015-10-28

Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer.

Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C, Goodstal S, Lim B, Bartholomeusz G, Ueno NT, Rao A.

J Cancer · research-article; journal article · DOI 10.7150/jca.13266

Bibliografisk träff 2015-09-18

AS-703026 Inhibits LPS-Induced TNFα Production through MEK/ERK Dependent and Independent Mechanisms.

Li P, Wu Y, Li M, Qiu X, Bai X, Zhao X.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0137107

Bibliografisk träff 2015-05-29

Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.

Inaba K, Oda K, Ikeda Y, Sone K, Miyasaka A, Kashiyama T, Fukuda T, Uehara Y, Arimoto T, Kuramoto H, Wada-Hiraike O, Kawana K, Yano T, Osuga Y, Fujii T.

Gynecol Oncol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ygyno.2015.05.031

Bibliografisk träff 2015-05-19

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.

Macarulla T, Cervantes A, Tabernero J, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Laffranchi B, Jego V, von Richter O, Ciardiello F.

Br J Cancer · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1038/bjc.2015.144

Bibliografisk träff 2013-12-01

The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells.

Park SJ, Hong SW, Moon JH, Jin DH, Kim JS, Lee CK, Kim KP, Hong YS, Choi EK, Lee JS, Lee JL, Kim TW.

Am J Med Sci · research support, non-u.s. gov't; journal article · DOI 10.1097/maj.0b013e318298a185